We’re proud to share that our clinical validation study, published earlier this year in Breast Cancer Research and Treatment, has been recognised as one of the journal’s top-performing articles, ranked in the 97th percentile for popularity.
The study highlights ground-breaking findings:
The study reports the prognostic performance of Digistain® for risk classification in HR+, HER2- breast cancer.
Dive into the details of our study and findings here:
In our ongoing effort to bring accessible cancer diagnostics to the regions that need them most, we are proud to announce the official launch of
We are thrilled to share that Digistain was hand selected by an expert panel of judges from EIT Health, AstraZeneca Spain, SERMAS and Hospital 12
It was an honour to take part in the recent Physics Deep Tech Showcase at Institute of Physics, hosted in partnership with the Venture Capital
Supported by:
To stay updated about Digistain’s developments, enter your details opposite. We promise only to send you important news.